S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
NASDAQ:MLAB

Mesa Laboratories (MLAB) Stock Price, News & Analysis

$107.11
-0.14 (-0.13%)
(As of 09:30 AM ET)
Today's Range
$107.11
$107.11
50-Day Range
$90.62
$114.10
52-Week Range
$82.86
$187.75
Volume
306 shs
Average Volume
50,392 shs
Market Capitalization
$577.32 million
P/E Ratio
630.10
Dividend Yield
0.60%
Price Target
$125.00

Mesa Laboratories MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
16.6% Upside
$125.00 Price Target
Short Interest
Healthy
3.64% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
1.31mentions of Mesa Laboratories in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
16.91%
From $6.15 to $7.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.47 out of 5 stars

Medical Sector

309th out of 939 stocks

Process Control Instruments Industry

9th out of 12 stocks

MLAB stock logo

About Mesa Laboratories Stock (NASDAQ:MLAB)

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

MLAB Stock Price History

MLAB Stock News Headlines

CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
Mesa Laboratories Inc.
Here's what Wall Street expects from Mesa Laboratories's earnings
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates
Earnings Preview: Mesa Laboratories
Andvari Associates Q4 2023 Letter
Mesa Laboratories Inc MLAB
Mesa Laboratories, Inc. (MLI.F)
See More Headlines
Receive MLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesa Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Ex-Dividend for 3/15 Dividend
2/28/2024
Dividend Payable
3/15/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Process control instruments
Sub-Industry
Electronic Equipment & Instruments
Current Symbol
NASDAQ:MLAB
CUSIP
59064R10
Employees
698
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$125.00
High Stock Price Target
$125.00
Low Stock Price Target
$125.00
Potential Upside/Downside
+16.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$930,000.00
Pretax Margin
-0.28%

Debt

Sales & Book Value

Annual Sales
$219.08 million
Cash Flow
$12.46 per share
Book Value
$73.60 per share

Miscellaneous

Free Float
5,114,000
Market Cap
$578.08 million
Optionable
Not Optionable
Beta
0.83
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

MLAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Mesa Laboratories stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mesa Laboratories in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MLAB shares.
View MLAB analyst ratings
or view top-rated stocks.

What is Mesa Laboratories' stock price target for 2024?

1 Wall Street research analysts have issued 1 year target prices for Mesa Laboratories' stock. Their MLAB share price targets range from $125.00 to $125.00. On average, they predict the company's stock price to reach $125.00 in the next twelve months. This suggests a possible upside of 16.6% from the stock's current price.
View analysts price targets for MLAB
or view top-rated stocks among Wall Street analysts.

How have MLAB shares performed in 2024?

Mesa Laboratories' stock was trading at $104.77 at the beginning of the year. Since then, MLAB shares have increased by 2.4% and is now trading at $107.25.
View the best growth stocks for 2024 here
.

Are investors shorting Mesa Laboratories?

Mesa Laboratories saw a drop in short interest in March. As of March 15th, there was short interest totaling 196,300 shares, a drop of 17.2% from the February 29th total of 237,200 shares. Based on an average trading volume of 52,800 shares, the short-interest ratio is presently 3.7 days.
View Mesa Laboratories' Short Interest
.

When is Mesa Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our MLAB earnings forecast
.

How were Mesa Laboratories' earnings last quarter?

Mesa Laboratories, Inc. (NASDAQ:MLAB) posted its quarterly earnings results on Monday, February, 5th. The medical instruments supplier reported $1.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.47 by $0.01. The medical instruments supplier earned $53.47 million during the quarter, compared to analysts' expectations of $54.90 million. Mesa Laboratories had a net margin of 0.45% and a trailing twelve-month return on equity of 7.41%.

How often does Mesa Laboratories pay dividends? What is the dividend yield for Mesa Laboratories?

Mesa Laboratories declared a quarterly dividend on Tuesday, January 2nd. Stockholders of record on Thursday, February 29th will be paid a dividend of $0.16 per share on Friday, March 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Wednesday, February 28th.
Read our dividend analysis for MLAB
.

Is Mesa Laboratories a good dividend stock?

Mesa Laboratories (NASDAQ:MLAB) pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.63%. The dividend payout ratio is 376.49%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MLAB will have a dividend payout ratio of 8.90% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MLAB.

What ETFs hold Mesa Laboratories' stock?

ETFs with the largest weight of Mesa Laboratories (NASDAQ:MLAB) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS).Motley Fool Small-Cap Growth ETF (TMFS).

What is Gary Owens' approval rating as Mesa Laboratories' CEO?

5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mesa Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and Company (BDX).

Who are Mesa Laboratories' major shareholders?

Mesa Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (10.73%), Vanguard Group Inc. (6.87%), Vanguard Group Inc. (6.86%), Ranger Investment Management L.P. (4.21%), Geneva Capital Management LLC (3.52%) and Dimensional Fund Advisors LP (2.36%). Insiders that own company stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Shannon Hall.
View institutional ownership trends
.

How do I buy shares of Mesa Laboratories?

Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLAB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners